A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

Trial Profile

A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs BPX 601 (Primary) ; Rimiducid
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 Based on data from the initial three treated patients in this trial, the Company, with support from the principal investigator and the FDA, amended the study protocol to allow activation of the iMC switch seven days following the administration of BPX-601 versus the previous 30-day schedule.
    • 21 Feb 2017 According to Bellicum Pharmaceuticals media release, first patient has been dosed in this trial.
    • 04 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top